BIOCARDIA, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.18 USD | +7.07% |
|
+8.02% | -67.58% |
| 01:00pm | CellProthera and BioCardia, Inc. Collaborate on Successful Phase II Trial of ProtheraCytes for the Treatment of Acute Myocardial Infarction | CI |
| Jun. 10 | Top Premarket Decliners | MT |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 52.33 | 25.12 | 49.2 | 32.73 | 41.9 | 15.69 |
| Enterprise Value (EV) 1 | 46.98 | 20.67 | 28.4 | 21.73 | 36.16 | 15.9 |
| P/E ratio | -3.29 x | -1.41 x | -2.33 x | -2.6 x | -3.11 x | -1.22 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 83.7 x | 35.4 x | 339 x | 32.2 x | 31 x | 32.9 x |
| EV / Revenue | 75.2 x | 29.1 x | 196 x | 21.4 x | 26.7 x | 33.3 x |
| EV / EBITDA | -3.35 x | -1.47 x | -1.84 x | -1.73 x | -3.06 x | -1.38 x |
| EV / FCF | -7.78 x | -4.28 x | -4.36 x | -3.74 x | -5.7 x | -2.64 x |
| FCF Yield | -12.8% | -23.4% | -23% | -26.7% | -17.5% | -37.9% |
| Price to Book | 13.8 x | 10.6 x | 2.94 x | 3.15 x | 8.58 x | -9.81 x |
| Nbr of stocks (in thousands) | 323 | 455 | 948 | 1,125 | 1,336 | 1,575 |
| Reference price 2 | 162.0 | 55.20 | 51.90 | 29.10 | 31.35 | 9.963 |
| Announcement Date | 4/2/19 | 4/9/20 | 3/30/21 | 3/29/22 | 3/29/23 | 3/27/24 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 0.625 | 0.71 | 0.145 | 1.015 | 1.352 | 0.477 |
| EBITDA 1 | -14.01 | -14.1 | -15.46 | -12.57 | -11.82 | -11.56 |
| EBIT 1 | -14.1 | -14.21 | -15.53 | -12.63 | -11.9 | -11.64 |
| Operating Margin | -2,256.32% | -2,001.83% | -10,709.66% | -1,244.33% | -880.25% | -2,441.09% |
| Earnings before Tax (EBT) 1 | -13.99 | -14.71 | -15 | -12.62 | -11.91 | -11.57 |
| Net income 1 | -13.99 | -14.71 | -15 | -12.62 | -11.91 | -11.57 |
| Net margin | -2,237.92% | -2,071.69% | -10,347.59% | -1,243.65% | -880.7% | -2,425.79% |
| EPS 2 | -49.20 | -39.09 | -22.24 | -11.19 | -10.08 | -8.195 |
| Free Cash Flow 1 | -6.036 | -4.832 | -6.52 | -5.806 | -6.34 | -6.028 |
| FCF margin | -965.72% | -680.58% | -4,496.9% | -572% | -468.94% | -1,263.63% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 4/2/19 | 4/9/20 | 3/30/21 | 3/29/22 | 3/29/23 | 3/27/24 |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 |
|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.079 | 0.06 | 0.974 | 0.212 | 0.106 | 0.064 | 0.043 | 0.357 | 0.013 |
| EBITDA 1 | -3.446 | -3.311 | -2.48 | -3.031 | -2.997 | -3.488 | -3.431 | -2.577 | -2.064 |
| EBIT 1 | -3.461 | -3.327 | -2.496 | -3.06 | -3.018 | - | -3.452 | -2.598 | -2.084 |
| Operating Margin | -4,381.01% | -5,545% | -256.26% | -1,443.4% | -2,847.17% | - | -8,027.91% | -727.73% | -16,030.77% |
| Earnings before Tax (EBT) 1 | -3.461 | -3.325 | -2.497 | -3.057 | -3.028 | -3.501 | -3.424 | -2.574 | -2.072 |
| Net income 1 | -3.461 | -3.325 | -2.497 | -3.057 | -3.028 | -3.501 | -3.424 | -2.574 | -2.072 |
| Net margin | -4,381.01% | -5,541.67% | -256.37% | -1,441.98% | -2,856.6% | -5,470.31% | -7,962.79% | -721.01% | -15,938.46% |
| EPS 2 | -3.150 | -2.850 | -2.100 | -2.550 | -2.400 | -2.550 | -2.550 | -1.800 | -1.350 |
| Dividend per Share | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/29/22 | 5/11/22 | 8/10/22 | 11/9/22 | 3/29/23 | 5/10/23 | 8/9/23 | 11/8/23 | 3/27/24 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | 0.21 |
| Net Cash position 1 | 5.36 | 4.44 | 20.8 | 11 | 5.73 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | -0.0183 x |
| Free Cash Flow 1 | -6.04 | -4.83 | -6.52 | -5.81 | -6.34 | -6.03 |
| ROE (net income / shareholders' equity) | -188% | -477% | -139% | -85.4% | -156% | -704% |
| ROA (Net income/ Total Assets) | -88.3% | -126% | -62.4% | -40.3% | -58.3% | -114% |
| Assets 1 | 15.83 | 11.67 | 24.04 | 31.3 | 20.42 | 10.16 |
| Book Value Per Share 2 | 11.70 | 5.210 | 17.60 | 9.220 | 3.650 | -1.020 |
| Cash Flow per Share 2 | 16.60 | 12.30 | 19.70 | 11.40 | 5.500 | 0.7000 |
| Capex 1 | 0.07 | 0.15 | 0.03 | 0.12 | 0.07 | 0.01 |
| Capex / Sales | 10.56% | 20.56% | 22.07% | 11.43% | 5.18% | 2.52% |
| Announcement Date | 4/2/19 | 4/9/20 | 3/30/21 | 3/29/22 | 3/29/23 | 3/27/24 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -70.19% | 5.42M | |
| +16.61% | 122B | |
| +17.75% | 112B | |
| +18.69% | 25.91B | |
| -24.11% | 19.33B | |
| -17.94% | 16.17B | |
| -18.47% | 15.6B | |
| -47.75% | 14.65B | |
| +57.35% | 14.34B | |
| +5.62% | 14B |
- Stock Market
- Equities
- BCDA Stock
- Financials BioCardia, Inc.
